Particularly, the authors found that temozolomide glioma resistant-cells secrete higher levels of Cx43 in sEVs promoting an increase in proliferation and Bcl-2 expression but reducing Bax and cleaved-caspase 3 in target cells. This evidence concerns the gene BCL2 and central nervous system cancer.